Ro 23-9424 is a broad-spectrum antibacterial agent consisting of a cephalosporin (desacetylcefotaxime) linked through an ester bond to a fluoroquinolone (fleroxacin). Its activity against mutants of Escherichia coli TE18 resistant to both antibacterial components was examined. E. coli TE18 overproduces the AmpC ,I-lactamase and is resistant to several cephalosporins, including desacetylcefotaxime (MIC, 50 ,ug/ml), although it is still susceptible to Ro 23-9424 (MIC, 0.2 ,ug/ml). Thirty-five spontaneous, two-step mutants of E. coli TE18 which were resistant to fleroxacin (MIC, 50 ,ig/ml) were isolated. In the mutants, replicative DNA biosynthesis (permeabilized cells) was resistant to fleroxacin, and some mutants had porin abnormalities.
Ro 23-9424 is a synthetic, broad-spectrum antibacterial agent consisting of a cephalosporin (desacetylcefotaxime) linked through an ester bond to a fluoroquinolone (fleroxacin). combines the antibacterial spectrum and potency of its two components (2, 3, 10, 14) . It binds to essential penicillin-binding proteins (PBPs) of Escherichia coli and Staphylococcus aureus (10) . It also inhibits replicative DNA biosynthesis and produces filamentation in E. coli (10) . However, it is unclear whether the intact molecule is responsible for the antibacterial activity. It has been suggested that Ro 23-9424 initially acts as a cephalosporin but that upon decomposition free fleroxacin is released and quinolone activity appears (10) . Considering that a low level of fleroxacin is present in the sera of animals receiving Ro 23-9424, it is plausible that, in vivo, the agent acts as a quinolone prodrug (14) . However, Ro 23-9424 may be more resistant to animal esterases than are esters of other cephalosporins and P-lactams (11, 15, 26) , as it is excreted predominantly intact in the urine of primates (14) . This study was undertaken to determine whether intact Ro 23-9424 can be responsible for the antibacterial effect in E. coli. To that end, fleroxacin-resistant mutants were selected from E. coli TE18. This strain is already resistant to the cephalosporin component, desacetylcefotaxime, because of AmpC P-lactamase overproduction (20) (Table 1) . Therefore, the mutants selected would be resistant to both decomposition products of Ro 23-9424, and any antibacterial activity should arise from the intact molecule. The parent strain, E. coli TE18, and the mutants were subsequently examined with respect to porn expression, permeability, P-lactamase activity, PBP profile, replicative DNA biosynthesis, and antibiotic susceptibility profile.
MATERIALS AND METHODS
Bacterial strains and bacteriophages. E. coli TE18, a K-12 strain containing the ampC gene and overproducing chromosomal 1-lactamase (20) , was kindly provided by S. Normark of Washington University (St. Louis, Mo.). E. coli ATCC Tables 1 and 2 . Predictably, the greatest increase in MICs was that of fleroxacin, where 50-and 500-fold increases were found for the first-step (JP28 to JP225) and second-step (JP28-1 to JP28-13) mutants, respectively. The first-step mutants were cross-resistant to other quinolones ( Table 2 ). The second-step mutants showed specific resistance to fleroxacin and ofloxacin; increases in MICs of other quinolones were about twofold ( (Table 3) , which was in turn lower than the Km for cephaloridine or cephalothin (Table 4) . Significantly, the hydrolysis rate of desacetylcefotaxime was more than 30 times greater than that of Ito (Table 3) . Cefotaxime was hydrolyzed at a rate approximately one-third that of Ro 23-9424, while cephaloridine and cephalothin were hydrolyzed at much higher rates. Km values for cephaloridine and cephalothin remained unchanged in the first-step (JP28) and second-step (JP28-1) mutants (Table 4) .
Outer membrane permeations of cephaloridine and cephalothin were also similar in E. coli TE18, JP28, and JP28-1 ( Table 4 ). The ability of Ro 23-9424 to permeate E. coli TE18 was substantially lower than the abilities of the related drugs cefotaxime and desacetylcefotaxime to do so (Table 3) .
Porin expression. Outer membrane protein profiles and susceptibilities to porin-specific bacteriophages indicated that the parent strain, TE18, had reduced levels of the OmpF porin relative to the levels in the reference strain, E. coli JF568 ( Fig. 1 and Table 5 ). Still, most of the fleroxacinresistant mutants expressed less than 7% of the OmpF protein found in TE18 (Table 5) . Quinolone uptake. There was a slight reduction in fleroxacin uptake in the first-step mutant JP28, and there was no reduction in uptake in the second-step mutant JP28-1 (data not shown).
PBP profiles. PBPs of E. coli TE18 and the fleroxacinresistant mutants were similar to those of E. coli DCO (Fig.  2) . Interestingly, fluorograms of polyacrylamide gels of TE18 as well as of the mutants showed an extra PBP with a molecular weight of approximately 37,000.
Replicative DNA biosynthesis. Replicative DNA biosynthesis was resistant to fleroxacin, pefloxacin, and Ro 23-9424 in strains JP28, JP28-1, and JP28-2, compared with E. coli TE18 ( Table 6 ). The 50% inhibitory concentrations of these compounds were 10-to 100-fold higher for the fleroxacinresistant mutants. The increase was most pronounced in the first-step mutants and only slight in the second-step mutants.
DISCUSSION
The cephalosporin 3'-quinolone ester Ro 23-9424 is a broad-spectrum antibacterial agent active both in vitro and in vivo (2, 3, 14) . The compound is bactericidal, free of inoculum effects, and active against cephalosporin-and quinolone-resistant organisms. Previous in vitro studies suggested that Ro 23-9424 acts both as a cephalosporin and as a quinolone prodrug (10) . However, these studies were complicated by the fact that Ro 23-9424 hydrolyzes to yield desacetylcefotaxime and fleroxacin, both of which possess antibacterial activity of their own. In fact, in many cases it is not entirely clear whether the intact molecule or its degradation products are responsible for the antibacterial activity (2, 14) . The present study sought to address this issue by examining E. coli mutants resistant to both the cephalosporin and quinolone components in order to examine antibacterial activity due solely to the intact Ro 23-9424.
The parent strain used in the study, E. coli TE18, is a K-12 strain previously reported to overproduce a chromosomally encoded AmpC ,3-lactamase and to have reduced susceptibility or outright resistance to a number of cephalosporins (20) . We found it to be highly resistant to desacetylcefotaxime, though not to Ro 23-9424 or cefotaxime (Table 1 ). In addition to the P-lactamase overproduction, the strain produced reduced amounts of the OmpF porin relative to the amount in E. coli JF568 (Table 5 and Figure 1 ), which might contribute to its cephalosporin resistance. Its PBP profile, though typical for an E. coli strain, included an extra 37,000-Da PBP which is probably the AmpC enzyme (4) .
Fleroxacin-resistant mutants were isolated from E. coli TE18 at a frequency higher than that previously reported for fleroxacin in E. coli JF568 (5) or for other quinolones (12, 13) . Predictably, the first-step mutants were cross-resistant to other quinolones, but surprisingly, the second-step mutants were cross-resistant only to the tricyclic quinolone ofloxacin. Resistance to amifloxacin was slightly reduced in the second-step mutants. The nature of this selectivity is at present unclear. In all fleroxacin-resistant mutants examined, the amounts of OmpF porin were reduced relative to the amount in TE18, and replicative DNA biosynthesis, an index of DNA gyrase activity, was resistant to quinolones. Similar effects have been shown in other quinolone-resistant gram-negative bacteria (1, 4, 7-9, 27, 28) . The clinical implications of OmpF porin reduction are unclear, as OmpF expression, and thus OmpF-associated permeability, is normally repressed by the high osmolarity and temperature which prevail in infections (19) . coli TE18 compared with other P-lactam antibiotics (Tables   3 and 4 ). This could be due to its large size (molecular (29) . Still, Ro 23-9424 must be able to pass through the outer membrane, as both the parent strain and the mutants were highly susceptible to it ( Table 1 ). The agent most likely enters through the OmpF porin channel (10) . Entry through the narrower OmpC porin channel might also be possible if Ro 23-9424 can assume a cylindrical conformation; such a conformation would permit a solute to enter through a channel with a radius smaller than the Stokes' radius of the solute (21) .
Ro 23-9424 probably does not pass through the outer membrane via the self-promoted pathway proposed for quinolones (6) , as there was no antagonism by magnesium (data not shown). Also, the lack of potentiation by transferrin under conditions in which MICs of catechol cephalosporins are reduced 10-fold (data not shown) precludes entry of Ro 23-9424 via the iron uptake pathway proposed for catechol-containing ,3-lactams (22) .
The P-lactamase stability of (Table 3) would permit it to diffuse intact through the periplasmic space and reach its target PBPs in E. coli TE18. The activity of Ro 23-9424 against desacetylcefotaxime-resistant, fleroxacinresistant E. coli is thus most likely due to its reduced hydrolysis by P-lactamase and its affinity for PBPs, which make it effective despite its poor ability to permeate the outer membrane (10) . The interplay of PBP affinity, outer membrane permeability, and ,-lactamase stability in producing the overall antibacterial effect has been recently studied quantitatively in E. coli for a number of 1-lactam antibiotics (20) . The relative stability of Ro 23-9424 against AmpC 1-lactamase may translate to other enterobacteria in which cephalosporins are hydrolyzed by chromosomal P-lactamases (25).
In conclusion, the susceptibility of E. coli strains to Ro 23-9424 but not to its degradation products, desacetylcefotaxime and fleroxacin, has allowed us to examine the activity of the intact molecule in a well-characterized organism. Ro 23-9424 acts in this case as a 1-lactamase-resistant cephalosporin. The present study could have clinical implications if the findings in preliminary animal studies suggesting that Ro 23-9424 is eliminated from the body largely intact (6a) are confirmed in humans.
